

Zoltan Szekanecz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6125540/publications.pdf>

Version: 2024-02-01

240
papers

12,620
citations

25034

57
h-index

29157

104
g-index

254
all docs

254
docs citations

254
times ranked

13431
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
2	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. <i>Rheumatology</i> , 2022, 61, 1783-1794.	1.9	31
3	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
4	Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2). <i>RMD Open</i> , 2022, 8, e002024.	3.8	5
5	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e13.	3.9	12
6	Effects of Classical Breathing Exercises on Posture, Spinal and Chest Mobility among Female University Students Compared to Currently Popular Training Programs. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3728.	2.6	7
7	Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 839374.	4.1	2
8	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. <i>Frontiers in Immunology</i> , 2022, 13, 846248.	4.8	19
9	Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 249-257.	8.0	23
10	Reflections on a contemporary European tragedy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 747-748.	0.9	2
11	Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.7	1
12	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 925-936.	0.9	59
13	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
14	Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of 1-year Antitumor Necrosis Factor- α Therapy. <i>Journal of Rheumatology</i> , 2021, 48, 821-828.	2.0	5
15	A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 81-89.	1.8	21
16	Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case-control study. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 70.	1.9	6
17	Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001765.	2.8	9
18	Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. <i>Osteoporosis International</i> , 2021, 32, 1621-1629.	3.1	26

#	ARTICLE	IF	CITATIONS
19	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	8.0	57
20	Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 325.	1.9	2
21	AB0160â€¦HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1107.1-1107.	0.9	0
22	OP0074â€¦A FRAMEWORK OF POTENTIAL INTERVENTIONS TO ACCELERATE GENDER-EQUITABLE CAREER ADVANCEMENT IN ACADEMIC RHEUMATOLOGY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 39.1-40.	0.9	1
23	POS0222â€¦PREDICTORS OF RESPONSE: BASELINE CHARACTERISTICS AND EARLY TREATMENT RESPONSES ASSOCIATED WITH ACHIEVEMENT OF REMISSION AND LOW DISEASE ACTIVITY AMONG UPADACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 329.2-330.	0.9	0
24	POS0383â€¦EFFECTS OF TOFACITINIB THERAPY ON ARGININE AND METHIONINE METABOLITES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS: A METABOLOMIC APPROACH. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 421.2-422.	0.9	1
25	Salivary citrullinated proteins in rheumatoid arthritis and associated periodontal disease. <i>Scientific Reports</i> , 2021, 11, 13525.	3.3	11
26	Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 585-595.	8.0	99
27	Associations of vascular and bone status in arthritis patients. <i>Scientific Reports</i> , 2021, 11, 19504.	3.3	3
28	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 817.	1.9	3
29	Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF- $\hat{\pm}$ Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. <i>Biomolecules</i> , 2021, 11, 1535.	4.0	11
30	Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. <i>Frontiers in Oncology</i> , 2021, 11, 725465.	2.8	7
31	Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status. <i>RMD Open</i> , 2021, 7, e001804.	3.8	10
32	Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients. <i>Frontiers in Medicine</i> , 2021, 8, 785744.	2.6	5
33	Effects of 1-year anti-TNF- $\hat{\pm}$ therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020, 39, 167-175.	2.2	50
34	Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. <i>Rheumatology International</i> , 2020, 40, 529-540.	3.0	19
35	A prospective, longitudinal monocentric study on laser Doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis. <i>Rheumatology International</i> , 2020, 40, 415-424.	3.0	7
36	Effects of 1-year anti-TNF- $\hat{\pm}$ therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. <i>Rheumatology International</i> , 2020, 40, 427-436.	3.0	42

#	ARTICLE	IF	CITATIONS
37	The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102421.	5.8	13
38	Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102658.	5.8	9
39	Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: Computer-aided versus conventional microscopic evaluation of routine diagnostic samples from patients with vasculitis or other inflammatory diseases. <i>Clinica Chimica Acta</i> , 2020, 511, 117-124.	1.1	6
40	Assessment of cervical spine involvement in rheumatoid arthritis patients in the era of biologics: a real-life, cross-sectional MRI study. <i>Rheumatology International</i> , 2020, 40, 915-921.	3.0	8
41	Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001032.	3.8	21
42	Reply to: Comment on "effects of 1-year anti-TNF- α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis" by Cure et al.. <i>Rheumatology International</i> , 2020, 40, 509-509.	3.0	0
43	Biosimilars: To switch or not to switch " that is the question. <i>Reumatologia</i> , 2020, 58, 1-3.	1.1	0
44	Cognitive dysfunction in autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2020, 22, 78.	3.5	28
45	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	2.2	6
46	The effects of breathing exercises in comparison with other exercise programs on cardiorespiratory fitness among healthy female college students. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 62-68.	0.7	2
47	Successful Treatment of Rheumatoid Arthritis-Associated Renal AA Amyloidosis with Tocilizumab. <i>Israel Medical Association Journal</i> , 2020, 22, 455-457.	0.1	1
48	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1056-1067.	0.8	1
49	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
50	Corneal Manifestations of Systemic Sclerosis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 968-977.	1.8	12
51	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	1.4	19
52	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
53	The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. <i>Archives of Biochemistry and Biophysics</i> , 2019, 670, 82-93.	3.0	60
54	Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 572-578.	2.0	2

#	ARTICLE	IF	CITATIONS
55	Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 340-341.	1.1	1
56	Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 94.	3.5	8
57	AB0689â€¦EVALUATION OF CARDIOVASCULAR DETERMINANTS OF DISEASE OUTCOME IN SYSTEMIC SCLEROSIS. , 2019, , .		0
58	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
59	Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 274.	3.5	11
60	Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. <i>Clinical Immunology</i> , 2019, 199, 47-51.	3.2	7
61	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Na ⁺ ve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	2.9	7
62	Common mechanisms and holistic care in atherosclerosis and osteoporosis. <i>Arthritis Research and Therapy</i> , 2019, 21, 15.	3.5	39
63	Effects of one-year anti-TNF-Î± therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides. <i>Rheumatology and Orthopedic Medicine</i> , 2019, 4, .	0.2	3
64	Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1010-1018.	0.8	1
65	Tocilizumab Treatment in Polyarteritis Nodosa. <i>Israel Medical Association Journal</i> , 2019, 21, 560-562.	0.1	5
66	Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content. <i>Lasers in Medical Science</i> , 2018, 33, 1225-1236.	2.1	0
67	Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. <i>Lupus</i> , 2018, 27, 1552-1558.	1.6	18
68	Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?. <i>Clinical Rheumatology</i> , 2018, 37, 1183-1188.	2.2	2
69	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
70	AB0840â€¦Determination of serum levels of and anti-drug antibody production against tnf inhibitors in ankylosing spondylitis: testing may be useful for the assessment of compliance but not that of treatment effectiveness. , 2018, , .		0
71	Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 95.	3.5	70
72	EULAR â€”points to considerâ€” TM for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16

#	ARTICLE	IF	CITATIONS
73	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.9	83
74	Editorial: Comorbidity Burden in Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 197.	2.6	13
75	Impact of obesity on autoimmune arthritis and its cardiovascular complications. <i>Autoimmunity Reviews</i> , 2018, 17, 821-835.	5.8	42
76	SAT0497â€¦Follow-up of disease activity in hungarian patients with idiopathic inflammatory myopathy. , 2018, , .		0
77	The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients. <i>Israel Medical Association Journal</i> , 2018, 20, 217-221.	0.1	0
78	Effects of targeted therapies on the bone in arthritides. <i>Autoimmunity Reviews</i> , 2017, 16, 313-320.	5.8	47
79	Cardiac Effects of Antirheumatic Drugs. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 489-529.	0.1	0
80	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
81	Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 521-529.	1.6	65
82	Ã‰valuation de lâ€™immunogÃ©nicitÃ© du vaccin pneumococcique conjuguÃ© 13-valent chez des patients atteints de polyarthrite rhumatoÃ¯de traitÃ©s par Ã©tanercept. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 418-422.	0.0	0
83	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.9	918
84	TLRs, future potential therapeutic targets for RA. <i>Autoimmunity Reviews</i> , 2017, 16, 103-113.	5.8	118
85	Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls. <i>Osteoporosis International</i> , 2017, 28, 1271-1277.	3.1	11
86	Pneumococcal vaccination in autoimmune rheumatic diseases. <i>RMD Open</i> , 2017, 3, e000484.	3.8	25
87	Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. <i>Rheumatology International</i> , 2017, 37, 1835-1845.	3.0	20
88	THU0694â€¦Effects of ANTI-TNF therapy on soluble urokinase plasminogen activator receptor (SUPAR) levels in arthritis. , 2017, , .		0
89	Development of temporomandibular joint arthritis: The use of animal models. <i>Joint Bone Spine</i> , 2017, 84, 145-151.	1.6	24
90	Effect of FcÎ³-receptor 3a (<i>FCGR3A</i>) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000485.	3.8	20

#	ARTICLE	IF	CITATIONS
91	AB0632â€¦Assessment of vegf and other cytokines in the tear of patients with systemic sclerosis. , 2017, , .		0
92	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 139-147.	1.9	15
93	Cell Recruitment and Angiogenesis. , 2017, , 384-395.e5.		0
94	Targeting Cannabinoid Signaling in the Immune System: â€œHighâ€•ly Exciting Questions, Possibilities, and Challenges. Frontiers in Immunology, 2017, 8, 1487.	4.8	111
95	Opportunities and challenges in rheumatology research in Central Europe. Arthritis Research and Therapy, 2017, 19, 196.	3.5	3
96	Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 213.	3.5	11
97	Posterior Reversible Encephalopathy Syndrome (PRES) Associated with Thrombotic Thrombocytopenic Purpura in a Systemic Lupus Erythematosus Patient. Israel Medical Association Journal, 2017, 19, 700-702.	0.1	0
98	Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis. Current Immunology Reviews, 2016, 12, 35-46.	1.2	12
99	Characterization and Localization of Citrullinated Proteoglycan Aggrecan in Human Articular Cartilage. PLoS ONE, 2016, 11, e0150784.	2.5	13
100	AB0312â€¦Predictors of Disease Course after The Discontinuation of Biologic Therapy in Rheumatoid Arthritis Patients with Long-Term Remission. Annals of the Rheumatic Diseases, 2016, 75, 1007.1-1007.	0.9	1
101	Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine, 2016, 83, 675-679.	1.6	32
102	OPO207â€¦Transmembrane TNF-Alpha Reverse Signaling Leading To TGF-Beta Production Is Selectively Activated by Anti-TNF-Alpha Targeting Molecules. Annals of the Rheumatic Diseases, 2016, 75, 135.1-135.	0.9	0
103	Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis. Immunologic Research, 2016, 64, 619-626.	2.9	14
104	Targeting of proangiogenic signalling pathways in chronic inflammation. Nature Reviews Rheumatology, 2016, 12, 111-122.	8.0	93
105	Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do. Autoimmunity Reviews, 2016, 15, 756-769.	5.8	45
106	Patientsâ€™ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Annals of the Rheumatic Diseases, 2016, 75, 942-943.	0.9	21
107	Transmembrane TNF-Î± Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-Î²: Therapeutic Implications. Journal of Immunology, 2016, 196, 1146-1157.	0.8	40
108	Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nature Reviews Rheumatology, 2016, 12, 5-13.	8.0	129

#	ARTICLE	IF	CITATIONS
109	FRI0144â€¦Analysis of the Association Between Cigarette Smoking and Clinical Response to Certolizumab Pegol Treatment in Hungarian Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 474.1-474.	0.9	1
110	AB0042â€¦Natural Autoantibodies Against Citrate Synthase and DNA Topoisomerase I in Patients with Rheumatoid Arthritis and Spondyloarthritis Receiving Anti-TNF-Î± Therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 904.1-904.	0.9	0
111	A8.13â€¦Natural autoantibodies against citrate synthase and DNA topoisomerase I in patients with rheumatoid arthritis and spondyloarthritis receiving anti-TNF-Î± therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A86.2-A86.	0.9	0
112	Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-4.	3.0	20
113	Combination of IgG <i>glycomics</i> and corresponding transcriptomics data to identify anti-TNF-Î± treatment responders in inflammatory diseases. <i>Electrophoresis</i> , 2015, 36, 1330-1335.	2.4	12
114	Occurrence of pulmonary rheumatoid nodules following biological therapies. <i>Clinical Rheumatology</i> , 2015, 34, 1639-1642.	2.2	9
115	Angiogenesis and vasculogenesis in rheumatoid arthritis. , 2015, , 764-767.		0
116	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. <i>Rheumatology</i> , 2014, 53, 2143-2154.	1.9	239
117	Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. <i>Rheumatology</i> , 2014, 53, 2035-2043.	1.9	12
118	Acceptability of less than perfect health states in rheumatoid arthritis: the patientsâ€™ perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	2.8	12
119	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	8.0	154
120	Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 281.	1.9	45
121	Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 623-629.	2.2	15
122	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	2.8	26
123	Biologics, cardiovascular effects and cancer. <i>BMC Medicine</i> , 2014, 12, 48.	5.5	14
124	Of mice and men: how animal models advance our understanding of T-cell function in RA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 160-170.	8.0	50
125	Suppression of Proteoglycan-Induced Autoimmune Arthritis by Myeloid-Derived Suppressor Cells Generated In Vitro from Murine Bone Marrow. <i>PLoS ONE</i> , 2014, 9, e111815.	2.5	34
126	Perspectives of pharmacological treatment in otosclerosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 793-804.	1.6	29

#	ARTICLE	IF	CITATIONS
127	Treatment of ankylosing spondylitis with biologics and targeted physical therapy. <i>Zeitschrift Fur Rheumatologie</i> , 2013, 72, 997-1004.	1.0	13
128	Pharmacogenetics and pharmacogenomics in rheumatology. <i>Immunologic Research</i> , 2013, 56, 325-333.	2.9	22
129	Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. <i>Immunologic Research</i> , 2013, 56, 439-443.	2.9	33
130	Genetics of Rheumatoid Arthritis – A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 170-179.	6.5	244
131	Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion. <i>Journal of Rheumatology</i> , 2013, 40, 565-571.	2.0	26
132	Clinical Course, Prognosis, and Causes of Death in Mixed Connective Tissue Disease. <i>Journal of Rheumatology</i> , 2013, 40, 1134-1142.	2.0	85
133	Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. <i>Genome Medicine</i> , 2013, 5, 59.	8.2	38
134	SAT0190 – Long-Term Follow-Up of 280 Patients with Mixed Connective Tissue Disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A645.2-A645.	0.9	1
135	A7.20 – Response to Infliximab Therapy can be Predicted using Distinct, Non-Overlapping Gene Panels of Peripheral Blood Gene Expression in Rheumatoid Arthritis and Crohn's Disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A55.1-A55.	0.9	1
136	AB0606 – Effects of 12-month etanercept or certolizumab pegol therapy on disease activity, bone turnover markers and peripheral qct bone mineral density in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A975.2-A975.	0.9	1
137	FRIO398 – Derailed b cell homeostasis in patients with mixed connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A508.1-A508.	0.9	0
138	Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immunocomplex production in patients with systemic sclerosis - a prospective case-series study. <i>Arthritis Research and Therapy</i> , 2013, 15, R105.	3.5	39
139	THU0399 – Effects of 12-Month Etanercept Therapy on Disease Activity, Bone Turnover Markers and Peripheral QCT Bone Mineral Density in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A300.2-A300.	0.9	1
140	Editorial paper Treatment strategies in rheumatoid arthritis. <i>Reumatologia</i> , 2013, 4, 239-248.	1.1	0
141	Cell Recruitment and Angiogenesis. , 2013, , 358-368.e5.		2
142	THU0196 – Disease Course after the Permanent Cessation of Biological Therapy in Inflammatory Rheumatic Diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A230.1-A230.	0.9	0
143	Atherosclerosis in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2012, 2012, 1-2.	3.0	7
144	Non-MHC Risk Alleles in Rheumatoid Arthritis and in the Syntenic Chromosome Regions of Corresponding Animal Models. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	10

#	ARTICLE	IF	CITATIONS
145	In Vivo Calcium and Phosphate Iontophoresis for the Topical Treatment of Osteoporosis. <i>Physical Therapy</i> , 2012, 92, 289-297.	2.4	7
146	Validated methods for assessment of subclinical atherosclerosis in rheumatology. <i>Nature Reviews Rheumatology</i> , 2012, 8, 224-234.	8.0	118
147	Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: Rituximab may be the right choice?. <i>Autoimmunity</i> , 2012, 45, 304-309.	2.6	12
148	Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
149	Malignancies associated with systemic sclerosis. <i>Autoimmunity Reviews</i> , 2012, 11, 852-855.	5.8	43
150	Peripheral Blood Gene Expression and IgG Glycosylation Profiles as Markers of Tocilizumab Treatment in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 916-928.	2.0	25
151	Associations entre lâ€™Ã©pitope partagÃ© de lâ€™HLA, les anticorps anti-peptide citrullinÃ© et les facteurs liÃ©s au mode de vie chez des patients hongrois atteints de polyarthrite rhumatoÃ©de: donnÃ©es de la premiÃ¨re cohorte de lâ€™Europe centrale et de lâ€™est. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 93-94.	0.0	0
152	Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy program in ankylosing spondylitis. <i>Rheumatology International</i> , 2012, 32, 3931-3936.	3.0	29
153	Prolactin and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 189-198.	6.5	52
154	Anti-mutated citrullinated vimentin (anti-MCV) and anti-65kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2012, 79, 63-66.	1.6	23
155	Anti-Inflammatory Therapeutic Approaches. , 2012, , 513-528.		1
156	Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. <i>Lupus</i> , 2011, 20, 730-735.	1.6	31
157	Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: Data from the first Central-Eastern European cohort. <i>Joint Bone Spine</i> , 2011, 78, 652-653.	1.6	7
158	Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. <i>Autoimmunity Reviews</i> , 2011, 10, 416-425.	5.8	98
159	Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 10, 490-494.	5.8	122
160	B-cells and their targeting in rheumatoid arthritis â€™ Current concepts and future perspectives. <i>Autoimmunity Reviews</i> , 2011, 11, 28-34.	5.8	85
161	Combination of peripheral blood gene expression profiles and clinical parameters predicts response to tocilizumab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A13-A14.	0.9	0
162	Assessment of Subclinical Vascular Disease Associated with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 723-729.	2.0	96

#	ARTICLE	IF	CITATIONS
163	Ex Vivo Soft-Laser Treatment Inhibits the Synovial Expression of Vimentin and β -Enolase, Potential Autoantigens in Rheumatoid Arthritis. <i>Physical Therapy</i> , 2011, 91, 665-674.	2.4	11
164	Malignancies in Autoimmune Rheumatic Diseases – A Mini-Review. <i>Gerontology</i> , 2011, 57, 3-10.	2.8	51
165	Ferritin and prolactin levels in multiple sclerosis. <i>Israel Medical Association Journal</i> , 2011, 13, 91-5.	0.1	34
166	Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2011, 13, 147-52.	0.1	31
167	Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. <i>Netherlands Journal of Medicine</i> , 2011, 69, 356-66.	0.5	32
168	Angiogenesis and vasculogenesis in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 299-306.	4.3	122
169	Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010, 9, 140-143.	5.8	160
170	New insights in synovial angiogenesis. <i>Joint Bone Spine</i> , 2010, 77, 13-19.	1.6	84
171	Development of natural calcium- and phosphate-donating microparticles and a new iontophoretic apparatus for the topical treatment of local osteoporosis. Preliminary in vitro and in vivo studies. <i>Joint Bone Spine</i> , 2010, 77, 426-431.	1.6	3
172	Actualités sur l'angiogenèse synoviale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 14-20.	0.0	0
173	Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. <i>BMC Medical Genomics</i> , 2010, 3, 15.	1.5	100
174	Chemokines and chemokine receptors in arthritis. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 153-167.	2.1	111
175	New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. <i>Rheumatology</i> , 2010, 49, 25-33.	1.9	28
176	Association of ARTS1 Gene Polymorphisms with Ankylosing Spondylitis in the Hungarian Population: The rs27044 Variant Is Associated with HLA-B*2705 Subtype in Hungarian Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 379-384.	2.0	45
177	Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1155-1157.	0.9	383
178	Biologics – beyond the joints. <i>Autoimmunity Reviews</i> , 2010, 9, 820-824.	5.8	31
179	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 325-331.	0.9	1,157
180	Effects of Biologics on Vascular Function and Atherosclerosis Associated with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 814-821.	3.8	38

#	ARTICLE	IF	CITATIONS
181	Angiogenesis and its targeting in rheumatoid arthritis. <i>Vascular Pharmacology</i> , 2009, 51, 1-7.	2.1	95
182	Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 705-710.	2.2	115
183	A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2009, 28, 655-662.	2.2	91
184	Plasma Homocysteine Levels, The Prevalence of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Macrovascular Disorders in Systemic Sclerosis: Risk Factors for Accelerated Macrovascular Damage?. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 145-149.	6.5	27
185	Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects. <i>Rheumatology International</i> , 2009, 29, 793-796.	3.0	28
186	Vascular effects of biologic agents in RA and spondyloarthropathies. <i>Nature Reviews Rheumatology</i> , 2009, 5, 677-684.	8.0	70
187	Angiogenesis in rheumatoid arthritis. <i>Autoimmunity</i> , 2009, 42, 563-573.	2.6	106
188	Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 26-31.	6.5	65
189	Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2008, 27, 1163-1166.	2.2	21
190	Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by cytokine-activated human aortic endothelial cells: a possible role for ICAM-1 and sICAM-1 in atherosclerotic aortic aneurysms. <i>Clinical and Experimental Immunology</i> , 2008, 98, 337-343.	2.6	53
191	Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1083-1090.	1.6	2
192	Vascular involvement in rheumatic diseases: 'vascular rheumatology'. <i>Arthritis Research and Therapy</i> , 2008, 10, 224.	3.5	144
193	Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices. <i>Journal of Autoimmunity</i> , 2008, 31, 372-376.	6.5	38
194	Survival and causes of death in 366 Hungarian patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 59-63.	0.9	101
195	Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 248-250.	0.9	122
196	Targeting Angiogenesis in Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2008, 4, 298-303.	0.8	27
197	Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. <i>Journal of Rheumatology</i> , 2008, 35, 398-406.	2.0	130
198	Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2008, 10, 32-6.	0.1	22

#	ARTICLE	IF	CITATIONS
199	Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. <i>Journal of Rheumatology</i> , 2008, 35, 1329-33.	2.0	42
200	Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 253-60.	0.8	37
201	Pro-inflammatory cytokines in atherosclerosis. <i>Israel Medical Association Journal</i> , 2008, 10, 529-30.	0.1	21
202	Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. <i>Rheumatology</i> , 2007, 46, 759-762.	1.9	119
203	Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 797-806.	3.0	4
204	Macrophages and their products in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 289-295.	4.3	275
205	Mechanisms of Disease: angiogenesis in inflammatory diseases. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 635-643.	3.2	178
206	Cardiac manifestations in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2007, 6, 379-386.	5.8	98
207	Novel Biomarkers in Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 385-400.	3.8	204
208	Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 349-358.	3.8	94
209	Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis: Potential Adhesion Molecules in Synovial Inflammation?. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 359-371.	3.8	39
210	Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1658-63.	2.0	52
211	Lupus and Cardiovascular Disease: The Facts. <i>Lupus</i> , 2006, 15, 3-10.	1.6	22
212	Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis. <i>Rheumatology International</i> , 2006, 26, 964-971.	3.0	45
213	Malignancies and soluble tumor antigens in rheumatic diseases. <i>Autoimmunity Reviews</i> , 2006, 6, 42-47.	5.8	58
214	Endothelial Cells in Inflammation and Angiogenesis. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 319-323.	3.1	34
215	HLA-DR genotypes in familial rheumatoid arthritis: increased frequency of protective and neutral alleles in a multicase family. <i>Journal of Rheumatology</i> , 2005, 32, 2299-302.	2.0	12
216	Antiphospholipid antibodies in acute coronary syndrome. <i>Lupus</i> , 2004, 13, 423-427.	1.6	65

#	ARTICLE	IF	CITATIONS
217	Vascular endothelium and immune responses: implications for inflammation and angiogenesis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 97-114.	1.9	71
218	Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 409-15.	0.8	33
219	Chemokines and angiogenesis. <i>Current Opinion in Rheumatology</i> , 2001, 13, 202-208.	4.3	135
220	Update on synovitis. <i>Current Rheumatology Reports</i> , 2001, 3, 53-63.	4.7	47
221	THU0010â€¦Vitamin d and oestrogen receptor polymorphism in rheumatoid arthritis. , 2001, , .		0
222	Temporal expression of inflammatory cytokines and chemokines in rat adjuvantâ€¦induced arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1266-1277.	6.7	156
223	Catastrophic antiphospholipid syndrome in cancer. <i>Haematologia</i> , 2000, 30, 303-311.	0.3	20
224	Cell-cell interactions in synovitis. Endothelial cells and immune cell migration. <i>Arthritis Research</i> , 2000, 2, 368.	2.0	45
225	Effects of Thrombospondin-1 on Disease Course and Angiogenesis in Rat Adjuvant-Induced Arthritis. <i>Clinical Immunology and Immunopathology</i> , 1998, 86, 199-208.	2.0	33
226	Chemokines in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1998, 20, 115-132.	4.0	87
227	Cytokines in Rheumatoid Arthritis. <i>Drugs and Aging</i> , 1998, 12, 377-390.	2.7	65
228	Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. <i>Journal of Investigative Medicine</i> , 1998, 46, 27-41.	1.6	40
229	Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.. <i>Journal of Clinical Pathology</i> , 1997, 50, 314-319.	2.0	17
230	Cellular adhesion molecules in rat adjuvant arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 810-819.	6.7	56
231	Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. <i>Journal of Investigative Medicine</i> , 1996, 44, 124-35.	1.6	29
232	Increased Synovial Expression of the Adhesion Molecules CD66a, CD66b, and CD31 in Rheumatoid and Osteoarthritis. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 180-186.	2.0	34
233	Increased Synovial Expression of Transforming Growth Factor (TGF)- β 2 Receptor Endoglin and TGF- β 1 in Rheumatoid Arthritis: Possible Interactions in the Pathogenesis of the Disease. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 187-194.	2.0	70
234	Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: The possible role for IL-6 and interferon-gamma in vascular inflammation. <i>Agents and Actions</i> , 1994, 42, 159-162.	0.7	128

#	ARTICLE	IF	CITATIONS
235	Differential Distribution of Intercellular Adhesion Molecules (ICAM ¹ , ICAM ² , and ICAM ³) and THE MS ¹ Antigen in Normal and Diseased Human Synovia. Arthritis and Rheumatism, 1994, 37, 221-231.	6.7	138
236	Interleukin-8 and Tumor Necrosis Factor-Alpha Are Involved in Human Aortic Endothelial Cell Migration. Pathobiology, 1994, 62, 134-139.	3.8	75
237	In situ Expression of Cytokines and Cellular Adhesion Molecules in the Skin of Patients with Systemic Sclerosis. Pathobiology, 1993, 61, 239-246.	3.8	166
238	Lymphocyte adhesion to high endothelium is mediated by two α 1 integrin receptors for fibronectin, α 4 β 1 and α 5 β 1. Journal of Cell Science, 1992, 101, 885-894.	2.0	30
239	Lymphocyte adhesion to high endothelium is mediated by two beta 1 integrin receptors for fibronectin, alpha 4 beta 1 and alpha 5 beta 1. Journal of Cell Science, 1992, 101 (Pt 4), 885-94.	2.0	7
240	Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases. Agents and Actions, 1991, 33, 254-259.	0.7	7